CClinicalTrials.gg
Not yet recruitingNCT06669468Updated Nov 1, 2024

Comparison of the Efficacy of Perineal and Anal Electrical Stimulation in Patients with Urinary Incontinence After Radical Prostatectomy

An interventional study of PFME and PFME + Anal ES in Prostatectomy and Urinary Incontinence, sponsored by Pamukkale University. Not yet recruiting at 1 site in Turkey. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Pamukkale University · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Male
01

Study summary

Radical prostatectomy (RP) is a common procedure for the treatment of prostate cancer. However, postoperative urinary incontinence (UI) is an important reason for morbidity. UI negatively affects the quality of life in 30-50% of patients, especially in the early period (3 weeks to 6 months). However, it takes approximately 1 year to achieve continence (1).

Conservative treatment methods include pelvic floor muscle exercises (PFME) with or without biofeedback (BF), anal and perineal electrical stimulation (ES), magnetic stimulation (MS), compression (penile clamps), lifestyle changes and combinations of these methods (2).

ES artificially stimulates the pudendal nerve and its branches to cause direct and reflex responses of the urethral and periurethral striated muscles in women. ES also inhibits detrusor overactivity (3,4). There is conflicting evidence as to whether the addition of ES to treatment increases the efficacy of PFME alone in patients with UI after RP (Level of evidence:1b), (5). However, ES may benefit PFME for up to six months (Level of evidence: 2b), (5). Non-neurogenic male incontinence guidelines recommend PFME alone or in combination with BF and/or ES for men undergoing RP to accelerate improvement of UI (5).

Many studies have shown that anal ES alone (1,7,8) or in combination with PFME (4,9,10,11) is more effective than untreated (4,7,9,11) or placebo ES (8,12). There are only two randomised controlled trials in the literature evaluating the efficacy of perineal ES in patients with UI after RP (13,14). In the study by Yıldız et al. (13), the group receiving perineal ES and the control group receiving no treatment were compared in patients who developed UI after RP. The results showed that incontinence severity, incontinence episodes, quality of life and anxiety parameters improved significantly in the 8th week in the group receiving perineal ES compared to the control group. In the study by Pané-Alemany et al. (14), a group receiving perianal ES and a group receiving anal ES were compared in patients who developed UI after RP. In the study, it was shown that the efficacy of the two treatments was not statistically different.

Our study is the first prospective randomised controlled trial to evaluate the efficacy of perineal and anal ES added to PFME in patients with UI after RP. The aim of this study was to evaluate the efficacy of perineal ES and anal ES added to PFME on clinical parameters related to UI, quality of life and sexual functions, depression and anxiety. In addition, patients' preparation time for stimulation, treatment satisfaction and discomfort levels will be evaluated.

Read the detailed description

The research will be conducted at Pamukkale University Physical Medicine and Rehabilitation (PMR) Department, Urogynecological Rehabilitation Unit between November 2024 and January 2025.

The study included 93 patients (described in detail in the statistics section) who accepted the treatment among the male patients who applied to Pamukkale University FTR Polyclinic with the complaint of UI after RP or who were referred to the Urogynecological Rehabilitation Unit by the Urology outpatient clinic and who met the inclusion criteria. Patients will be informed about the content, purpose and application of the study and their written consent will be obtained.

At the beginning of the study, age, height, weight, education level, occupation, marital status, previous operations, systemic diseases, alcohol, tea, coffee, coffee, cigarette use and medications will be questioned in patients who applied to Pamukkale University FTR Polyclinic or Urology Polyclinic with the complaint of UI after RP and referred to the Urogynecological Rehabilitation Unit. The type of UI (stress, urge, mixed, drip) will be determined in all patients participating in the study.

Patients will be advised to continue their medical treatments for reasons other than incontinence during the treatment period. No lifestyle modification recommendations regarding urinary function will be given during the treatment period and participants will be instructed not to change their habits during the 8-week period of the study.

Ninety-three male patients who meet the inclusion and exclusion criteria after RP will be randomly divided into three groups using a random number table. The first group will receive PFME, the second group will receive PFME + anal ES, and the third group will receive PFME + perineal ES.

Group 1: PFME Group 2: PFME + anal ES Group 3: PFME + perineal ES

02

Conditions studied

  • Prostatectomy
  • Urinary Incontinence

Keywords

  • Anal Electrical Stimulation
  • Perineal Electrical Stimulation
  • Radical Prostatectomy
  • İncontinence
03

In context

Urinary Incontinence

1,363 studies on the registry are indexed under Urinary Incontinence; 228 are open to participants now.

This study's planned enrollment of 93 is above the median of 66 across 1,011 interventional studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

Pamukkale University is the lead sponsor of 331 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • 18-80 years old
  • Men with RP with incontinence over >50 g/24 h and no residual cancer after RP on pathological examination
  • Men within 1 month to 1 year after catheter removal
  • Willingness to complete and do the QoL scale.
  • Understanding procedures, benefits, and possible side effects.
  • Being able to give written, informed consent.

Exclusion criteria

Exclusion Criteria:

  • UI history before RP.
  • History of conservative treatment after RP including ES.
  • Prolonged indwelling urethral catheterization (more than 15 days).
  • Previous urological surgery history.
  • Men receiving radiotherapy.
  • Presence of urethral stricture and urinary tract infection.
  • Heart failure, presence of a pacemaker, implanted defibrillator.
  • Transurethral resection of the prostate due to benign prostatic hyperplasia.
  • Use of drugs that may affect bladder function (antimuscarinic, duloxetine, tricyclic antidepressant, etc.).
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
93 participants (estimated)

Study arms

  • Active comparator
    Group 1: PFME

    The patients were instructed to do as an home exercise program in first 2 weeks, 5 s contraction and 10 s relaxation, including two sets of 5 repetition daily, in following 2 weeks 10 s contraction and 20 s relaxation, including two sets of 10 repetition daily, and after 4 weeks, 10 s contraction and 20 s relaxation including three sets of 10 repetition daily in three different position (lying, sitting, and standing). So in the first 2 weeks 30 contractions daily, in following 2 weeks 60 contractions daily and upward 4th weeks, 90 contractions daily with progressively increasing intensity was done. All patients were asked to mark the exercise at a daily home schedule. Patients who did not complete more than 20% of the list according to the daily home program were excluded from the study.

    Other: PFME

  • Experimental
    Group 2: PFME + Anal ES

    Anal ES was applied in the lithotomy position by means of a combined electrotherapy (stimulation) device with anal electrodes. Anal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks. Stimulation parameters were 50 Hz frequency, 5-10 s work-rest cycle and 300 µs pulse amplitude. Symmetrical biphasic pulse wave was given in the range of 1-100 mA (according to the patient's discomfort level feedback). In this procedure, it was applied with an anal probe placed in the anal region. Patients did not perform voluntary contractions during ES. Anal probes were used separately for each patient. Anal ES sessions were performed by an investigator participating in the study. Men who missed any treatment session for the stimulation group were excluded from the study.

    Other: PFME + Anal ES

  • Experimental
    Group 3: PFME + Perineal ES

    Perineal ES was applied in the lithotomy position by means of a combined electrotherapy (stimulation) device with surface electrodes. Anal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks. Stimulation parameters were 50 Hz frequency, 5-10 s work-rest cycle and 300 µs pulse amplitude. Symmetrical biphasic pulse wave was given in the range of 1-100 mA (according to the patient's discomfort level feedback). In this procedure, five surface electrodes with a diameter of 2 cm will be used, four electrodes symmetrically in the perianal region and one electrode in the leg (ground-neutral electrode). Patients will not perform voluntary contractions during ES. Surface electrodes will be used separately for each patient. Perineal ES sessions were performed by an investigator participating in the study. Men who missed any treatment session for the stimulation group were excluded from the study.

    Other: PFME + Perineal ES

Interventions

  • OtherPFME

    All patients were asked to mark the exercise at a daily home schedule. Patients who did not complete more than 20% of the list according to the daily home program were excluded from the study.

  • OtherPFME + Anal ES

    Anal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks.

  • OtherPFME + Perineal ES

    Perineal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Severity of incontinence

    The 24-hour pad test was carried out to evaluate urinary loss.

    Time frame: 8 weeks

Secondary outcomes

  1. Incontinence episodes

    Patients with a 50% or greater reduction in incontinence episodes were consider improvement

    Time frame: 8 weeks

  2. Three-day Bladder Diary

    It was used "frequency of voiding", "incontinence episodes", "nocturia", "number of pads" from data collected with a 3-day bladder diary.

    Time frame: 8 weeks

  3. Quality of Life - Incontinence Impact Questionnaire (IIQ-7)

    The IIQ-7 scale which has great validity in studies was used to assess the patient's QoL associated with incontinence problem

    Time frame: 8 weeks

  4. Level of sexual function - International Index of Erectile Function (IIEF)

    Sexual functions

    Time frame: 6 weeks

  5. Level of Anxiety and Depression - Hospital Anxiety and Depression Scale (HAD)

    Anxiety and Depression

    Time frame: 8 weeks

  6. Treatment satisfaction - Likert scale (1-5 )

    The patients evaluated the change of their urinary incontinence on a 5-point Likert scale (5, very satisfied; 4, satisfied; 3, equally satisfied and unsatisfied; 2, unsatisfied; 1, very unsatisfied)

    Time frame: 8 weeks

  7. Treatment Success (Continence rate)

    Patients with ≤8 gr in 24-hour pad test measurement will be considered "continent"

    Time frame: 8 weeks

  8. Cure (Dry) and Improvement Rate

    the absence of will be evaluated as "dryness"

    Time frame: 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06669468
Lead sponsor
Pamukkale University
Responsible party
Necmettin Yildiz (Professor Doctor, Pamukkale University) — Principal investigator
First posted
Nov 1, 2024
Start date
Nov 30, 2024 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Nov 1, 2024

Study contacts

Serhat ÖTKEN M.D. M.D.
Contact
serhatotkenn@gmail.com
+905412260861
Necmettin YILDIZ Prof.
study director · Pamukkale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion